Authors:
Treon, SP
Mitsiades, C
Mitsiades, N
Young, G
Doss, D
Schlossman, R
Anderson, KC
Citation: Sp. Treon et al., Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies, J IMMUNOTH, 24(3), 2001, pp. 263-271
Authors:
Mitsiades, N
Mitsiades, CS
Poulaki, V
Anderson, KC
Treon, SP
Citation: N. Mitsiades et al., Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma andother neoplasias, EXPERT OP I, 10(8), 2001, pp. 1521-1530
Authors:
Mitsiades, N
Poulaki, V
Mitsiades, CS
Anderson, KC
Citation: N. Mitsiades et al., Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors:new tricks from a (not so) old drug, EXPERT OP I, 10(6), 2001, pp. 1075-1084
Authors:
Poulaki, V
Mitsiades, N
Mastorakos, G
Caspi, RR
Chrousos, GP
Bouzas, E
Citation: V. Poulaki et al., Fas/Fas Ligand-associated apoptosis in experimental autoimmune uveoretinitis in rodents: Role of proinflammatory corticotropin-releasing hormone, EXP EYE RES, 72(6), 2001, pp. 623-629
Authors:
Mitsiades, N
Poulaki, V
Mitsiades, C
Tsokos, M
Citation: N. Mitsiades et al., Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5, CANCER RES, 61(6), 2001, pp. 2704-2712
Authors:
Mitsiades, N
Yu, WH
Poulaki, V
Tsokos, M
Stamenkovic, I
Citation: N. Mitsiades et al., Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity, CANCER RES, 61(2), 2001, pp. 577-581
Authors:
Poulaki, V
Mitsiades, N
Romero, ME
Tsokos, M
Citation: V. Poulaki et al., Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and bcl-2, CANCER RES, 61(12), 2001, pp. 4864-4872
Authors:
Mitsiades, CS
Treon, SP
Mitsiades, N
Shima, Y
Richardson, P
Schlossman, R
Hideshima, T
Anderson, KC
Citation: Cs. Mitsiades et al., TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications, BLOOD, 98(3), 2001, pp. 795-804
Authors:
Mitsiades, N
Poulaki, V
Tseleni-Balafouta, S
Chrousos, GP
Koutras, DA
Citation: N. Mitsiades et al., Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease, THYROID, 10(7), 2000, pp. 527-532
Authors:
Orban, Z
Mitsiades, N
Burke, TR
Tsokos, M
Chrousos, GP
Citation: Z. Orban et al., Caffeic acid phenethyl ester induces leukocyte apoptosis, modulates nuclear factor-kappa B and suppresses acute inflammation, NEUROIMMUNO, 7(2), 2000, pp. 99-105
Authors:
Marino, M
Chiovato, L
Mitsiades, N
Latrofa, F
Andrews, D
Tseleni-Balafouta, S
Collins, AB
Pinchera, A
McCluskey, RT
Citation: M. Marino et al., Circulating thyroglobulin transcytosed by thyroid cells is complexed with secretory components of its endocytic receptor megalin, J CLIN END, 85(9), 2000, pp. 3458-3467
Authors:
Mitsiades, N
Poulaki, V
Tseleni-Balafouta, S
Koutras, DA
Stamenkovic, I
Citation: N. Mitsiades et al., Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand, CANCER RES, 60(15), 2000, pp. 4122-4129
Authors:
Mitsiades, N
Poulaki, V
Leone, A
Tsokos, M
Citation: N. Mitsiades et al., Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors, J NAT CANC, 91(19), 1999, pp. 1678-1684
Authors:
Mitsiades, N
Poulaki, V
Mastorakos, G
Tseleni-Balafouta, S
Kotoula, V
Koutras, DA
Tsokos, M
Citation: N. Mitsiades et al., Fas ligand expression in thyroid carcinomas: A potential mechanism of immune evasion, J CLIN END, 84(8), 1999, pp. 2924-2932
Authors:
Mitsiades, N
Poulaki, V
Kotoula, V
Leone, A
Tsokos, M
Citation: N. Mitsiades et al., Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase, AM J PATH, 153(6), 1998, pp. 1947-1956